NICU Antibiotics and Outcomes (NANO) Follow-up Study

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

802

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Premature BirthAntibioticsNeurodevelopment
Interventions
DRUG

Ampicillin

Intravenous Ampicillin

DRUG

Gentamicin

Intravenous Gentamicin

DRUG

Placebo

Intravenous Normal Saline

Trial Locations (15)

10027

Columbia University, New York

10595

Westchester Medical Center, Valhalla

11203

State University of New York Downstate, Brooklyn

14611

University of Rochester, Rochester

15213

Magee-Womens Hospital, Pittsburgh

The University of Pittsburgh Medical Center, Pittsburgh

19104

The Children's Hospital of Philadelphia, Philadelphia

19107

Jefferson Medical College of Thomas Jefferson University, Philadelphia

33620

University of South Florida, Tampa

40292

University of Louisville, Louisville

78229

University of Texas Health Science Center at San Antonio, San Antonio

92123

Sharp Mary Birch Hospital for Women & Newborns, San Diego

06511

Yale University, New Haven

17033-0850

The Pennsylvania State University, Hershey

Unknown

Sinai Health System, Toronto

All Listed Sponsors
collaborator

University of Pittsburgh

OTHER

collaborator

Morgan Stanley Children's Hospital

OTHER

collaborator

University of Louisville

OTHER

collaborator

Sharp Mary Birch Hospital for Women & Newborns

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Jefferson Medical College of Thomas Jefferson University

OTHER

collaborator

University of South Florida

OTHER

collaborator

Westchester Medical Center

OTHER

collaborator

Yale University

OTHER

collaborator

The University of Texas Health Science Center at San Antonio

OTHER

collaborator

Penn State University

OTHER

collaborator

State University of New York - Downstate Medical Center

OTHER

collaborator

Mount Sinai Hospital, Canada

OTHER

lead

Sharp HealthCare

OTHER